Lung Cancer
Volume 68, Issue 1 , Pages 58-65 , April 2010

LAT1 expression in non-small-cell lung carcinomas: Analyses by semiquantitative reverse transcription-PCR (237 cases) and immunohistochemistry (295 cases)

  • Katsuyuki Takeuchi

      Affiliations

    • Division of Molecular Pharmacology, Department of Biosystems Science, Graduate School of Science and Technology, Kobe University, Nada 657-8601, Japan
    • ,
  • Sho Ogata

      Affiliations

    • Department of Pathology and Laboratory Medicine, National Defense Medical College, Tokorozawa 359-8513, Japan
    • ,
  • Kuniaki Nakanishi

      Affiliations

    • Department of Pathology and Laboratory Medicine, National Defense Medical College, Tokorozawa 359-8513, Japan
    • Corresponding Author InformationCorresponding author at: Department of Pathology and Laboratory Medicine, National Defense Medical College, Tokorozawa 359-8513, Japan. Tel.: +81 42 995 1505; fax: +81 42 996 5192.
    • ,
  • Yuichi Ozeki

      Affiliations

    • Department of Surgery, National Defense Medical College, Tokorozawa 359-8513, Japan
    • ,
  • Sadayuki Hiroi

      Affiliations

    • Department of Pathology and Laboratory Medicine, National Defense Medical College, Tokorozawa 359-8513, Japan
    • ,
  • Susumu Tominaga

      Affiliations

    • Department of Pathology and Laboratory Medicine, National Defense Medical College, Tokorozawa 359-8513, Japan
    • ,
  • Shinsuke Aida

      Affiliations

    • Department of Laboratory Medicine, National Defense Medical College Hospital, Tokorozawa 359-8513, Japan
    • ,
  • Hirotaka Matsuo

      Affiliations

    • Department of Physiology, National Defense Medical College, Tokorozawa 359-8513, Japan
    • ,
  • Tsuneaki Sakata

      Affiliations

    • Division of Molecular Pharmacology, Department of Biology, Graduate School of Science, Kobe University, Nada 657-8601, Japan
    • ,
  • Toshiaki Kawai

      Affiliations

    • Department of Pathology and Laboratory Medicine, National Defense Medical College, Tokorozawa 359-8513, Japan

Received 12 December 2008 ,Revised 26 March 2009 ,Accepted 28 May 2009.

References 

  1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66
  2. Toloza EM, D’Amico TA. Targeted therapy for non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2005;17:199–204
  3. Christensen HN. Role of amino acid transport and countertransport in nutrition and metabolism. Physiol Rev. 1990;70:43–77
  4. Chillaron J, Roca R, Valencia A, Zorzano A, Palacin M. Heteromeric amino acid transporters: biochemistry, genetics, and physiology. Am J Physiol Renal Physiol. 2000;281:F995–F1018
  5. Kanai Y, Endou H. Functional properties of multispecific amino acid transporters and their implications to transporter-mediated toxicity. J Toxicol Sci. 2003;28:1–17
  6. Kanai Y, Endou H. Heterodimeric amino acid transporters: molecular biology and pathological and pharmacological relevance. Curr Drug Metab. 2001;2:339–354
  7. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem. 1998;273:23629–23632
  8. Mastroberardino L, Spindler B, Pfeiffer R, Skelly PJ, Loffing J, Shoemaker CB, et al. Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family. Nature. 1998;395:288–291
  9. Ohkame H, Masuda H, Ishii Y, Kanai Y. Expression of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in liver tumor lesions of rat models. J Surg Oncol. 2001;78:265–271
  10. Parmacek MS, Karpinski BA, Gottesdiener KM, Thompson CB, Leiden JM. Structure, expression and regulation of the murine 4F2 heavy chain. Nucleic Acids Res. 1989;17:1915–1931
  11. Sang J, Lim YP, Panzica M, Finch P, Thompson NL. TA1, a highly conserved oncofetal complementary DNA from rat hepatoma, encodes an integral membrane protein associated with liver development, carcinogenesis, and cell activation. Cancer Res. 1995;55:1152–1159
  12. Shennan DB, Thomson J, Barber MC, Travers MT. Functional and molecular characteristics of system L in human breast cancer cells. Biochim Biophys Acta. 2003;1611:81–90
  13. Campbell WA, Thompson NL. Overexpression of LAT1/CD98 light chain is sufficient to increase system l-amino acid transport activity in mouse hepatocytes but not fibroblasts. J Biol Chem. 2001;276:16877–16884
  14. Nakanishi K, Matsuo H, Kanai Y, Endou H, Hiroi S, Tominaga S, et al. LAT1 expression in normal lung and in atypical adenomatous hyperplasia and adenocarcinoma of the lung. Virchows Arch. 2006;448:142–150
  15. Travis WD, Colby TV, Corrin B, Shimosato T, Brambilla E. The World Health Organization: Histological Typing of Lung and Pleural Tumours. third ed.. 1999;p. 36
  16. Sobin IH, Wittekind C. International Union against Cancer: TNM Classification of Malignant Tumours. 6th ed.. New York: Wiley-Liss Inc.; 2002;
  17. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, et al. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I–III nonsmall cell lung cancer. Br J Cancer. 2008;98:742–748
  18. Matsuo H, Tsukada S, Nakata T, Chairoungdua A, Kim DK, Cha SH, et al. Expression of a system L neutral amino acid transporter at the blood-brain barrier. Neuroreport. 2000;11:3507–3511
  19. Segawa H, Fukasawa Y, Miyamoto K, Takeda E, Endou H, Kanai Y. Identification and functional characterization of a Na+-independent neutral amino acid transporter with broad substrate selectivity. J Biol Chem. 1999;274:19745–19751

PII: S0169-5002(09)00322-5

doi: 10.1016/j.lungcan.2009.05.020

Lung Cancer
Volume 68, Issue 1 , Pages 58-65 , April 2010

Article Tools

* Image Usage & Resolution